Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Principal Open-Label Study to Compare the Brain Uptake of [18F]Flutemetamol With Brain Amyloid Levels Determined Post-Mortem

Trial Profile

A Principal Open-Label Study to Compare the Brain Uptake of [18F]Flutemetamol With Brain Amyloid Levels Determined Post-Mortem

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jan 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Flutemetamol-F-18 (Primary)
  • Indications Alzheimer's disease
  • Focus Diagnostic use; Registrational
  • Sponsors GE Healthcare
  • Most Recent Events

    • 30 Jun 2014 The CHMP of the EMA provided a positive opinion on the MAA for Vizamyl indicated for PET imaging of the brain to estimate beta amyloid neuritic plaque density in patients evaluated for Alzheimer's disease.
    • 06 Nov 2013 New trial record
    • 25 Oct 2013 Data presented at Alzheimer's Association International Conference 2012 (AAIC-2012) and the American Academy of Neurology's (AAN) 64th Annual Meeting, according to GE Healthcare.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top